Abandoning clinical trial safeguards won’t boost local industry by Komesaroff, P et al.
1 | P a g e  
 
This article was published online by The Conversation. It is available online at 
https://theconversation.com/abandoning-clinical-trial-safeguards-wont-boost-local-industry-14847 . 
This work is licenced under a CC BY-NC 3.0, http://creativecommons.org/licenses/by-nd/3.0/  
 
 
 
7 October 2013, 6.30am AEST  
Abandoning clinical trial safeguards won’t 
boost local industry  
 
Paul Komesaroff, Colin Thomson, Ian Kerridge  
Testing new drugs in clinical trials is a billion-dollar industry in Australia, with most of the 
money coming from international pharmaceutical companies. But as investment grows in 
India, China, and other emerging competitors, some people argue we need to make Australia 
more attractive to such investment. One of their solutions is to water down the ethics 
approval process. 
Responding to these concerns, the Coalition’s election policy on medical research promises 
to “move swiftly” with reforms to the ways in which clinical trials are conducted, by 
developing: 
a nationally consistent approach to ethical standards to reduce complexity, speed up 
the process and where possible, rationalise the number of ethics committees to 
reduce the large number that currently exist. 
Before major changes are introduced, however, it is important to remember that ethics 
committees are the very bodies that ensure the safety of clinical trials and maintain public 
confidence. 
Developed in response to concerns about the untrammelled power of medical institutions in 
the 1970s, as well as reports of egregious excesses by researchers in the United States and 
elsewhere, the ethics committee system has become highly refined in both its processes and 
in the substance of the issues it addresses. 
In Australia, it is also remarkably devolved and democratic, drawing in thousands of men and 
women from different walks of life across the country to engage in conversation, for no 
personal gain, about ethical issues in health care and research. 
Established by hospitals and universities, the panels review research proposals and ensure 
they’re ethically acceptable. Their deliberations cover potential risks and benefits to both 
individuals and the wider society and issues relating to consent, confidentiality, privacy, 
conflicts of interest and protection of vulnerable participants. 
2 | P a g e  
 
Criticisms of the ethics committee system 
Critics of the system complain about the time and expense involved in the ethics review 
process and the added burdens it allegedly imposes on researchers and drug companies. They 
argue that it creates delays, adds to costs and acts as a disincentive to investment. 
They draw particular attention to alleged difficulties associated with obtaining approval for 
multi-centre trials – that is, trials conducted at several sites simultaneously – because of 
unnecessary duplication and frequent inconsistent outcomes. 
It is generally concluded that all these problems would be solved by replacing the present 
decentralised system with a centralised committee system that has authority to make 
decisions for the entire country. 
None of these criticisms is well founded and it is possible that the proposed solution may be 
both counterproductive and inappropriate – particularly where research must take account of 
local concerns, such as is the case with multi-site Indigenous health research. 
In fact, the evidence shows ethics committees in Australia operate with remarkable 
efficiency, with the time between submission and approval of a project often occurring in no 
more than a few weeks. 
And the ethics review process is generally concluded well in advance of other essential 
organisational processes, such as legal approval, establishment of insurance policies, and 
other governance decisions, including those concerning institutional commitments, staffing 
and logistic issues. 
Concerns over multi-centre trials may have once been well founded, but this is long past. A 
single national application form has been in place for more than five years and there are well-
established coordinating mechanisms at both the state and national levels to allow unified 
ethics review processes. 
In comparison with world standards, the system is economical and the times to approval are 
comparable with best practice elsewhere in the world. 
Global trends 
Over the past 15 years, the number of new clinical trials approved in Australia has been 
relatively static – not in decline as is sometimes claimed. But the reason for this has nothing 
to do with ethics committees or the ethics review process. 
Rather, approval of new trials reflects primarily the prevailing economic conditions – with a 
predicable drop having occurred worldwide during the global financial crisis of 2008 to 2009 
- and the changing attractiveness of Australia in response to fluctuations in the value of the 
dollar. 
Most importantly, the development of a thriving clinical research capacity in India, China, 
South-East Asia, Latin America, Brazil, Russia and Eastern Europe – many of which are 
grappling with very similar problems - has meant that an increasing volume of work is being 
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undertaken in these countries. Indeed, the Australian experience has been mirrored almost 
exactly by that of the United States and the European Union. 
Retaining trust in clinical trials 
So, would dismantling or watering down the ethics review system attract more research 
dollars to Australia? This is highly unlikely. Not only would it have no impact on the factors 
mentioned above but it’s likely to undermine the high levels of public trust and confidence on 
which recruitment of patients for clinical studies critically depends. 
The sense that essential protections are being weakened in order to increase investment 
income may well cause irreparable damage to the status and prestige of clinical research in 
this country. 
This is not to say that the present system is perfect. Attempts to improve the efficiency of 
data collection – such as electronic systems for collecting, processing and storing data – can 
help to keep prices down as well as assist with monitoring and improving safety. 
Recent initiatives to make it easier for members of the community to participate in clinical 
research, such as ClinicalTrialsConnect, are welcome and will no doubt also improve the 
efficiency of recruitment. But changes such as this will not reverse the large scale global 
trends to which we are all subject. 
We need to continue the debate about how to maximise research investment. But we can’t 
lose sight of the great contribution the ethics committee process, and the men and women 
who constitute it, makes to ensuring the safety of drug development and the continuing high 
status of the research enterprise in Australia. 
Attempts to undermine or destroy the ethics committee system will ultimately be harmful to 
all of us. 
 
